One To Watch

Formycon

A Germany-based biosimilar specialist developing and commercializing follow-on versions of high-revenue biologics, with an emphasis on ophthalmology and immunology. The company combines in-house biosimilar development with partner-led commercialization in major markets.

Company Overview

Formycon AG develops biosimilars to established biologic medicines and supports programs from early development through regulatory approval, supply chain setup and lifecycle management. It operates with a lean “platform” model, monetizing assets through licensing and commercialization partnerships.

Headquarters and Global Presence

Formycon is headquartered in Germany and operates globally through development activities and commercial partners that handle market launches and distribution in their regions.

Founding and History

Formycon was founded in 2012 and has transitioned from a development-only biosimilar company to a commercial-stage biosimilar business following the first market launch of FYB201 and subsequent regulatory approvals for additional assets.

Therapy Areas and Focus

Formycon is not a therapeutics innovator; it focuses on biosimilar versions of reference biologics in large, established markets. Its current portfolio is concentrated in:

Ophthalmology (retinal diseases treated with intravitreal biologics)
Immunology (autoimmune diseases treated with monoclonal antibodies)

Technology Platforms and Modalities

Formycon’s core capabilities are biosimilar development and CMC execution, including:

Analytical and clinical comparability packages for monoclonal antibody biosimilars
Regulatory execution across the US, EU and UK
Commercial readiness support (manufacturing strategy, supply chain, product presentation and lifecycle work)

Products and Clinical Pipeline

FYB201 (ranibizumab; Lucentis biosimilar)

Status: marketed in multiple territories via partners
Notable lifecycle: launch of an EMA-approved pre-filled syringe presentation in Europe, rolled out starting in France (October 2025) with additional countries planned in a staged approach

FYB202 (ustekinumab; Stelara biosimilar)

Status: approved and launched; marketed by a commercialization partner in the US and EU from QI 2025 (per company disclosures)
Regulatory feature: US interchangeability designation (effective April 30, 2025) has been highlighted by the company and partner

FYB203 (aflibercept; Eylea biosimilar)

Status: regulatory approvals in major markets including the US, EU and UK
Commercialization: partner-led, with launch timing and territory access dependent on market-by-market readiness and legal/regulatory conditions

FYB206 (undisclosed reference product in public summaries)

Status: clinical-stage program disclosed as having entered clinical development (company has described initiation of the clinical phase)

Strategic Partnerships

Formycon’s commercial model relies on regional commercialization partners that typically lead launches and sales while Formycon supports supply and ongoing lifecycle work. Disclosed partners include Teva (ranibizumab in Europe; aflibercept in parts of Europe/Israel), Fresenius Kabi (ustekinumab), and other territory-specific arrangements for certain assets.

Key Personnel

Stefan Glombitza, Chief Executive Officer

FAQ Section

Formycon develops biosimilars of established biologics and monetizes them through partner-led commercialization. The company’s value creation is driven by efficient development timelines, regulatory execution in highly regulated markets, and reliable manufacturing and supply planning.

The current portfolio is concentrated in ophthalmology (retinal biologics) and immunology (autoimmune biologics), reflecting the size of the reference markets and the suitability of monoclonal antibodies for biosimilar development.

Formycon has three advanced biosimilar assets with approvals and/or launches: FYB201 (ranibizumab), FYB202 (ustekinumab) and FYB203 (aflibercept). Commercial availability varies by territory based on partner launch sequencing.

Most recent items, in reverse chronological order:

October 2025: European rollout began for FYB201/Ranivisio in an EMA-approved pre-filled syringe presentation, starting in France with additional countries planned in a staged launch.
April 30, 2025: FYB202 (ustekinumab; Otulfi in the US) received an interchangeability designation effective for corresponding dosage forms (as disclosed by the company/partner).
February 25, 2025: UK regulator approval announced for FYB203 (aflibercept) under the brand name AHZANTIVE.
2024 reporting period: Formycon described initiation of the clinical phase for FYB206 in its annual reporting.

For intravitreal ophthalmology products, presentation and ease-of-use can influence uptake. A pre-filled syringe format is positioned as a lifecycle and differentiation lever within an increasingly competitive ranibizumab biosimilar market.

Interchangeability is a US regulatory designation that can facilitate substitution at the pharmacy level, subject to state laws and payer/formulary policies. In practice, commercial impact depends on contracting, payer decisions and channel execution.

The most relevant milestones are execution-driven rather than single clinical readouts:

Additional country launches and uptake trends for FYB201 in Europe
Launch sequencing and market access progress for FYB202 across major markets
Territory-by-territory commercialization progress for FYB203
Advancement and disclosure milestones for FYB206 as it progresses through clinical development

Want to Update your Company's Profile?